<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464672</url>
  </required_header>
  <id_info>
    <org_study_id>V71P5</org_study_id>
    <secondary_id>IND: 13299</secondary_id>
    <nct_id>NCT00464672</nct_id>
  </id_info>
  <brief_title>Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old</brief_title>
  <official_title>A Phase III, Observer-Blind, Randomized, Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Immunogenicity of Two Trivalent Subunit Inactivated Influenza Vaccines in Healthy Children Aged 3 to 8 Years, in Healthy Children/Adolescents Aged 9 to 17 Years,and in Healthy Adults Aged 18 to 64 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is designed to evaluate safety, clinical tolerability and immunogenicity of the
      2007 southern hemisphere formulation of a Novartis conventional influenza vaccine licensed in
      the EU and many other worldwide countries, according to the US FDA Draft Guidance for
      Industry &quot;Clinical data needed to support the licensure of trivalent inactivated influenza
      vaccine&quot;, issued in March 2006, and to evaluate safety, clinical tolerability and
      immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional
      influenza vaccine already licensed in US. The purpose of the control arm is primarily to
      provide a comparative assessment for safety, not immunogenicity or effectiveness.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Seroprotection, in Healthy Adults 18 to 64 Years of Age</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>To evaluate immunogenicity, measured by seroprotection (percentage of subjects achieving a hemagglutination inhibition [HI] titer ≥40) after one injection of the investigational influenza virus vaccine, administered to healthy adults 18 to 64 years of age. The CBER Guidance states that the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroprotection meet or exceed 70%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving a Seroconversion Rate, in Adults 18 to 64 Years of Age</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum [HI&lt;10]/ post-vaccination HI titer ≥40) or significant increase defined as at least a 4-fold increase). According to the CBER Guidance, the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconverion/significant increase meet or exceed 40%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Symptoms in Adults 18 to 64 Years of Age</measure>
    <time_frame>7 days after vaccination</time_frame>
    <description>Solicited local and systemic reactions were assessed after vaccination in adults 18 to 64 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Seroprotection, in Healthy Children/Adolescents 9 to 17 Years of Age</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>To descriptively evaluate immunogenicity, measured by seroprotection rate (percentage of subjects achieving a hemagglutination inhibition [HI] titer ≥40) after one injection of investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Seroconversion Rate, in Healthy Children/Adolescents 9 to 17 Years of Age</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum [HI&lt;10]/ post-vaccination HI titer ≥40) or significant increase (defined as at least a 4-fold increase) after one injection of the investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs), in Healthy Children/Adolescents 9 to 17 Years of Age</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>To evaluate immunogenicity measured by GMTs after one injection of investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Symptoms in Children/Adolescents 9 to 17 Years of Age</measure>
    <time_frame>7 days after vaccination</time_frame>
    <description>Solicited local and systemic reactions were assessed after vaccination in children/adolescents 9 to 17 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Seroprotection, in Healthy Children 3 to 8 Years of Age</measure>
    <time_frame>50 days after last vaccination</time_frame>
    <description>To descriptively evaluate immunogenicity, measured by seroprotection rate (percentage of subjects achieving a hemagglutination inhibition [HI] titer ≥40) after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Seroconversion Rate, in Healthy Children 3 to 8 Years of Age</measure>
    <time_frame>50 days after last vaccination</time_frame>
    <description>Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum [HI&lt;10]/ post-vaccination HI titer ≥40) or significant increase (defined as at least a 4-fold increase) after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs), in Healthy Children 3 to 8 Years of Age</measure>
    <time_frame>50 days after last vaccination</time_frame>
    <description>To evaluate immunogenicity measured by GMTs after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number or Subjects Reporting Solicited Local and Systemic Symptoms, in Healthy Children 3 to 8 Years of Age.</measure>
    <time_frame>7 days after each vaccination</time_frame>
    <description>Solicited local and systemic reactions were assessed after each vaccination, in healthy children 3 to 8 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs), in Healthy Adults 18 to 64 Years of Age</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Immunogenicity measured by GMTs after one injection of the investigational influenza virus vaccine, in healthy adults 18 to 64 years of age.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1893</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Influenza virus vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza virus vaccine</intervention_name>
    <description>Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.</description>
    <arm_group_label>Influenza virus vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator influenza vaccine</intervention_name>
    <description>Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.</description>
    <arm_group_label>Comparator influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects 3 to 64 years of age

        Exclusion Criteria:

          -  Receipt of other investigational products within 3 months or other vacine within 1
             month;

          -  Allergy to eggs, egg products, or any other vaccine component;

          -  Laboratory confirmed influenza disease within 6 months;

          -  Have previously received an influenza vaccination (3 to 8 years only);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 2: C1425AWK</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1: X5000BJH</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2007</study_first_submitted>
  <study_first_submitted_qc>April 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2007</study_first_posted>
  <results_first_submitted>January 25, 2010</results_first_submitted>
  <results_first_submitted_qc>April 9, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2010</results_first_posted>
  <disposition_first_submitted>August 3, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>August 3, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 10, 2009</disposition_first_posted>
  <last_update_submitted>September 16, 2015</last_update_submitted>
  <last_update_submitted_qc>September 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2015</last_update_posted>
  <responsible_party>
    <name_title>Novartis Vaccines and Diagnostics</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Influenza, Egg-Derived, Healthy Children, Healthy Adolescents, Healthy Adults, Safety, Immunogenicity, Trivalent, Inactivated, Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Approximately 6 weeks for enrollment with date of first enrolment on April 2007</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Influenza Virus Vaccine (18 to 64 Years)</title>
          <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
        </group>
        <group group_id="P2">
          <title>Comparator Influenza Vaccine (18 to 64 Years)</title>
          <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
        </group>
        <group group_id="P3">
          <title>Influenza Virus Vaccine (9 to 17 Years)</title>
          <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
        </group>
        <group group_id="P4">
          <title>Comparator Influenza Vaccine (9 to 17 Years)</title>
          <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
        </group>
        <group group_id="P5">
          <title>Influenza Virus Vaccine (3 to 8 Years)</title>
          <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
        </group>
        <group group_id="P6">
          <title>Comparator Influenza Vaccine (3 to 8 Years)</title>
          <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="460"/>
                <participants group_id="P2" count="232"/>
                <participants group_id="P3" count="400"/>
                <participants group_id="P4" count="200"/>
                <participants group_id="P5" count="402"/>
                <participants group_id="P6" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="435"/>
                <participants group_id="P2" count="222"/>
                <participants group_id="P3" count="400"/>
                <participants group_id="P4" count="199"/>
                <participants group_id="P5" count="392"/>
                <participants group_id="P6" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Influenza Virus Vaccine</title>
          <description>Injections of the investigational influenza virus vaccine were administered intramuscularly</description>
        </group>
        <group group_id="B2">
          <title>Comparator Influenza Vaccine</title>
          <description>Injections of the comparator influenza vaccine were administered intramuscularly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1262"/>
            <count group_id="B2" value="631"/>
            <count group_id="B3" value="1893"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Chilren 3 to 8 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="1.7"/>
                    <measurement group_id="B2" value="5.4" spread="1.7"/>
                    <measurement group_id="B3" value="5.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Children/Adolescents 9 to 17 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.7" spread="2.6"/>
                    <measurement group_id="B2" value="12.8" spread="2.6"/>
                    <measurement group_id="B3" value="12.7" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adults 18 to 64 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="14.4"/>
                    <measurement group_id="B2" value="37.8" spread="12.6"/>
                    <measurement group_id="B3" value="38.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="575"/>
                    <measurement group_id="B2" value="294"/>
                    <measurement group_id="B3" value="869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="687"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="1024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1168"/>
                    <measurement group_id="B2" value="579"/>
                    <measurement group_id="B3" value="1747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Seroprotection, in Healthy Adults 18 to 64 Years of Age</title>
        <description>To evaluate immunogenicity, measured by seroprotection (percentage of subjects achieving a hemagglutination inhibition [HI] titer ≥40) after one injection of the investigational influenza virus vaccine, administered to healthy adults 18 to 64 years of age. The CBER Guidance states that the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroprotection meet or exceed 70%.</description>
        <time_frame>21 days after vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine (A/H1N1)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine (A/H3N2)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Influenza Virus Vaccine (Strain B)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O4">
            <title>Comparator Influenza Vaccine (A/H1N1)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O5">
            <title>Comparator Influenza Vaccine (A/H3N2)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O6">
            <title>Comparator Influenza Vaccine (Strain B)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroprotection, in Healthy Adults 18 to 64 Years of Age</title>
          <description>To evaluate immunogenicity, measured by seroprotection (percentage of subjects achieving a hemagglutination inhibition [HI] titer ≥40) after one injection of the investigational influenza virus vaccine, administered to healthy adults 18 to 64 years of age. The CBER Guidance states that the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroprotection meet or exceed 70%.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Percentages of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="424"/>
                <count group_id="O4" value="219"/>
                <count group_id="O5" value="219"/>
                <count group_id="O6" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="90" upper_limit="95"/>
                    <measurement group_id="O2" value="96" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O3" value="91" lower_limit="87" upper_limit="93"/>
                    <measurement group_id="O4" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O6" value="86" lower_limit="81" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving a Seroconversion Rate, in Adults 18 to 64 Years of Age</title>
        <description>Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum [HI&lt;10]/ post-vaccination HI titer ≥40) or significant increase defined as at least a 4-fold increase). According to the CBER Guidance, the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconverion/significant increase meet or exceed 40%.</description>
        <time_frame>21 days after vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine (A/H1N1)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine (A/H3N2)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Influenza Virus Vaccine (Strain B)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O4">
            <title>Comparator Influenza Vaccine (A/H1N1)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O5">
            <title>Comparator Influenza Vaccine (A/H3N2)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O6">
            <title>Comparator Influenza Vaccine (Strain B)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving a Seroconversion Rate, in Adults 18 to 64 Years of Age</title>
          <description>Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum [HI&lt;10]/ post-vaccination HI titer ≥40) or significant increase defined as at least a 4-fold increase). According to the CBER Guidance, the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconverion/significant increase meet or exceed 40%.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="424"/>
                <count group_id="O4" value="219"/>
                <count group_id="O5" value="219"/>
                <count group_id="O6" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="69" upper_limit="78"/>
                    <measurement group_id="O2" value="72" lower_limit="68" upper_limit="76"/>
                    <measurement group_id="O3" value="77" lower_limit="72" upper_limit="81"/>
                    <measurement group_id="O4" value="86" lower_limit="81" upper_limit="90"/>
                    <measurement group_id="O5" value="89" lower_limit="84" upper_limit="92"/>
                    <measurement group_id="O6" value="74" lower_limit="68" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Symptoms in Adults 18 to 64 Years of Age</title>
        <description>Solicited local and systemic reactions were assessed after vaccination in adults 18 to 64 years of age.</description>
        <time_frame>7 days after vaccination</time_frame>
        <population>The analysis was performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Comparator Influenza Vaccine</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Symptoms in Adults 18 to 64 Years of Age</title>
          <description>Solicited local and systemic reactions were assessed after vaccination in adults 18 to 64 years of age.</description>
          <population>The analysis was performed on the safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="460"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Seroprotection, in Healthy Children/Adolescents 9 to 17 Years of Age</title>
        <description>To descriptively evaluate immunogenicity, measured by seroprotection rate (percentage of subjects achieving a hemagglutination inhibition [HI] titer ≥40) after one injection of investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.</description>
        <time_frame>21 days after vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine (A/H1N1)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine (A/H3N2)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Influenza Virus Vaccine (Strain B)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O4">
            <title>Comparator Influenza Vaccine (A/H1N1)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O5">
            <title>Comparator Influenza Vaccine (A/H3N2)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O6">
            <title>Comparator Influenza Vaccine (Strain B)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroprotection, in Healthy Children/Adolescents 9 to 17 Years of Age</title>
          <description>To descriptively evaluate immunogenicity, measured by seroprotection rate (percentage of subjects achieving a hemagglutination inhibition [HI] titer ≥40) after one injection of investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Percentage of subjects</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="393"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O3" value="93" lower_limit="90" upper_limit="95"/>
                    <measurement group_id="O4" value="98" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O6" value="89" lower_limit="84" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving Seroconversion Rate, in Healthy Children/Adolescents 9 to 17 Years of Age</title>
        <description>Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum [HI&lt;10]/ post-vaccination HI titer ≥40) or significant increase (defined as at least a 4-fold increase) after one injection of the investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.</description>
        <time_frame>21 days after vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP)population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine (A/H1N1)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine (A/H3N2)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Influenza Virus Vaccine (Strain B)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O4">
            <title>Comparator Influenza Vaccine (A/H1N1)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O5">
            <title>Comparator Influenza Vaccine (A/H3N2)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O6">
            <title>Comparator Influenza Vaccine (Strain B)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Seroconversion Rate, in Healthy Children/Adolescents 9 to 17 Years of Age</title>
          <description>Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum [HI&lt;10]/ post-vaccination HI titer ≥40) or significant increase (defined as at least a 4-fold increase) after one injection of the investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.</description>
          <population>The analysis was performed on the per-protocol (PP)population.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="393"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="88" upper_limit="94"/>
                    <measurement group_id="O2" value="67" lower_limit="62" upper_limit="72"/>
                    <measurement group_id="O3" value="81" lower_limit="76" upper_limit="84"/>
                    <measurement group_id="O4" value="91" lower_limit="86" upper_limit="94"/>
                    <measurement group_id="O5" value="92" lower_limit="87" upper_limit="95"/>
                    <measurement group_id="O6" value="73" lower_limit="67" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs), in Healthy Children/Adolescents 9 to 17 Years of Age</title>
        <description>To evaluate immunogenicity measured by GMTs after one injection of investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.</description>
        <time_frame>21 days after vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP)population</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine (A/H1N1)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine (A/H3N2)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Influenza Virus Vaccine (Strain B)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O4">
            <title>Comparator Influenza Vaccine (A/H1N1)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O5">
            <title>Comparator Influenza Vaccine (A/H3N2)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O6">
            <title>Comparator Influenza Vaccine (Strain B)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs), in Healthy Children/Adolescents 9 to 17 Years of Age</title>
          <description>To evaluate immunogenicity measured by GMTs after one injection of investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.</description>
          <population>The analysis was performed on the per-protocol (PP)population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="393"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="960" lower_limit="857" upper_limit="1076"/>
                    <measurement group_id="O2" value="493" lower_limit="453" upper_limit="536"/>
                    <measurement group_id="O3" value="144" lower_limit="127" upper_limit="163"/>
                    <measurement group_id="O4" value="1246" lower_limit="1058" upper_limit="1467"/>
                    <measurement group_id="O5" value="1463" lower_limit="1296" upper_limit="1651"/>
                    <measurement group_id="O6" value="114" lower_limit="95" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Symptoms in Children/Adolescents 9 to 17 Years of Age</title>
        <description>Solicited local and systemic reactions were assessed after vaccination in children/adolescents 9 to 17 years of age.</description>
        <time_frame>7 days after vaccination</time_frame>
        <population>The analysis was performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine</title>
            <description>Injection of the investigational influenza virus vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Comparator Influenza Vaccine</title>
            <description>Injection of the comparator influenza vaccine were administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Symptoms in Children/Adolescents 9 to 17 Years of Age</title>
          <description>Solicited local and systemic reactions were assessed after vaccination in children/adolescents 9 to 17 years of age.</description>
          <population>The analysis was performed on the safety population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Seroprotection, in Healthy Children 3 to 8 Years of Age</title>
        <description>To descriptively evaluate immunogenicity, measured by seroprotection rate (percentage of subjects achieving a hemagglutination inhibition [HI] titer ≥40) after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.</description>
        <time_frame>50 days after last vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine (A/H1N1)</title>
            <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine (A/H3N2)</title>
            <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Influenza Virus Vaccine (Strain B)</title>
            <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O4">
            <title>Comparator Influenza Vaccine (A/H1N1)</title>
            <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O5">
            <title>Comparator Influenza Vaccine (A/H3N2)</title>
            <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O6">
            <title>Comparator Influenza Vaccine (Strain B)</title>
            <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroprotection, in Healthy Children 3 to 8 Years of Age</title>
          <description>To descriptively evaluate immunogenicity, measured by seroprotection rate (percentage of subjects achieving a hemagglutination inhibition [HI] titer ≥40) after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.</description>
          <population>The analysis was performed on the per-protocol (PP) population</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="149"/>
                <count group_id="O5" value="149"/>
                <count group_id="O6" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O3" value="85" lower_limit="80" upper_limit="89"/>
                    <measurement group_id="O4" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O5" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O6" value="81" lower_limit="73" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving Seroconversion Rate, in Healthy Children 3 to 8 Years of Age</title>
        <description>Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum [HI&lt;10]/ post-vaccination HI titer ≥40) or significant increase (defined as at least a 4-fold increase) after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.</description>
        <time_frame>50 days after last vaccination</time_frame>
        <population>The analysis was performed on the per protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine (A/H1N1)</title>
            <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine (A/H3N2)</title>
            <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Influenza Virus Vaccine (Strain B)</title>
            <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O4">
            <title>Comparator Influenza Vaccine (A/H1N1)</title>
            <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O5">
            <title>Comparator Influenza Vaccine (A/H3N2)</title>
            <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O6">
            <title>Comparator Influenza Vaccine (Strain B)</title>
            <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Seroconversion Rate, in Healthy Children 3 to 8 Years of Age</title>
          <description>Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum [HI&lt;10]/ post-vaccination HI titer ≥40) or significant increase (defined as at least a 4-fold increase) after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.</description>
          <population>The analysis was performed on the per protocol (PP) population.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="149"/>
                <count group_id="O5" value="149"/>
                <count group_id="O6" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="91" upper_limit="97"/>
                    <measurement group_id="O2" value="86" lower_limit="82" upper_limit="90"/>
                    <measurement group_id="O3" value="83" lower_limit="78" upper_limit="87"/>
                    <measurement group_id="O4" value="97" lower_limit="92" upper_limit="99"/>
                    <measurement group_id="O5" value="95" lower_limit="90" upper_limit="98"/>
                    <measurement group_id="O6" value="79" lower_limit="72" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs), in Healthy Children 3 to 8 Years of Age</title>
        <description>To evaluate immunogenicity measured by GMTs after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.</description>
        <time_frame>50 days after last vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP)population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine (A/H1N1)</title>
            <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine (A/H3N2)</title>
            <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Influenza Virus Vaccine (Strain B)</title>
            <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O4">
            <title>Comparator Influenza Vaccine (A/H1N1)</title>
            <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O5">
            <title>Comparator Influenza Vaccine (A/H3N2)</title>
            <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
          </group>
          <group group_id="O6">
            <title>Comparator Influenza Vaccine (Strain B)</title>
            <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs), in Healthy Children 3 to 8 Years of Age</title>
          <description>To evaluate immunogenicity measured by GMTs after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.</description>
          <population>The analysis was performed on the per-protocol (PP)population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="149"/>
                <count group_id="O5" value="149"/>
                <count group_id="O6" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625" lower_limit="532" upper_limit="734"/>
                    <measurement group_id="O2" value="710" lower_limit="637" upper_limit="792"/>
                    <measurement group_id="O3" value="157" lower_limit="133" upper_limit="185"/>
                    <measurement group_id="O4" value="716" lower_limit="570" upper_limit="898"/>
                    <measurement group_id="O5" value="1472" lower_limit="1263" upper_limit="1715"/>
                    <measurement group_id="O6" value="126" lower_limit="100" upper_limit="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number or Subjects Reporting Solicited Local and Systemic Symptoms, in Healthy Children 3 to 8 Years of Age.</title>
        <description>Solicited local and systemic reactions were assessed after each vaccination, in healthy children 3 to 8 years of age.</description>
        <time_frame>7 days after each vaccination</time_frame>
        <population>The analysis was performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine (Injection 1)</title>
            <description>Injections of the investigational influenza virus vaccine were administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Influenza Vaccine (Injection 1)</title>
            <description>Injections of the comparator influenza vaccine were administered intramuscularly.</description>
          </group>
          <group group_id="O3">
            <title>Influenza Virus Vaccine (Injection 2)</title>
            <description>Injections of the investigational influenza virus vaccine were administered intramuscularly.</description>
          </group>
          <group group_id="O4">
            <title>Comparator Influenza Vaccine (Injection 2)</title>
            <description>Injections of the comparator influenza vaccine were administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number or Subjects Reporting Solicited Local and Systemic Symptoms, in Healthy Children 3 to 8 Years of Age.</title>
          <description>Solicited local and systemic reactions were assessed after each vaccination, in healthy children 3 to 8 years of age.</description>
          <population>The analysis was performed on the safety population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="396"/>
                <count group_id="O4" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs), in Healthy Adults 18 to 64 Years of Age</title>
        <description>Immunogenicity measured by GMTs after one injection of the investigational influenza virus vaccine, in healthy adults 18 to 64 years of age.</description>
        <time_frame>21 days after vaccination</time_frame>
        <population>The analysis was done on the per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine (A/H1N1)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine (A/H3N2)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Influenza Virus Vaccine (Strain B)</title>
            <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O4">
            <title>Comparator Influenza Vaccine (A/H1N1)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O5">
            <title>Comparator Influenza Vaccine (A/H3N2)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
          <group group_id="O6">
            <title>Comparator Influenza Vaccine (Strain B)</title>
            <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs), in Healthy Adults 18 to 64 Years of Age</title>
          <description>Immunogenicity measured by GMTs after one injection of the investigational influenza virus vaccine, in healthy adults 18 to 64 years of age.</description>
          <population>The analysis was done on the per protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="424"/>
                <count group_id="O4" value="219"/>
                <count group_id="O5" value="219"/>
                <count group_id="O6" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244" lower_limit="214" upper_limit="278"/>
                    <measurement group_id="O2" value="219" lower_limit="196" upper_limit="245"/>
                    <measurement group_id="O3" value="126" lower_limit="113" upper_limit="140"/>
                    <measurement group_id="O4" value="512" lower_limit="426" upper_limit="615"/>
                    <measurement group_id="O5" value="485" lower_limit="415" upper_limit="567"/>
                    <measurement group_id="O6" value="104" lower_limit="90" upper_limit="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited adverse events were collected from 21 days after the last vaccination (up to day 53) to study termination (up to day 216). All serious adverse events were collected throughout the entire study period (up to day 216).</time_frame>
      <desc>One subject (18 years of age) in the comparator influenza vaccine group was enrolled in the adolescent age strata but was included in the adult age stratum for the safety analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Influenza Virus Vaccine (18 to 64 Years)</title>
          <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
        </group>
        <group group_id="E2">
          <title>Comparator Influenza Vaccine (18 to 64 Years)</title>
          <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
        </group>
        <group group_id="E3">
          <title>Influenza Virus Vaccine (9 to 17 Years)</title>
          <description>One injection of the investigational influenza virus vaccine was administered intramuscularly</description>
        </group>
        <group group_id="E4">
          <title>Comparator Influenza Vaccine (9 to 17 Years)</title>
          <description>One injection of the comparator influenza vaccine was administered intramuscularly</description>
        </group>
        <group group_id="E5">
          <title>Influenza Virus Vaccine (3 to 8 Years)</title>
          <description>Two injections of the investigational influenza virus vaccine were administered intramuscularly</description>
        </group>
        <group group_id="E6">
          <title>Comparator Influenza Vaccine (3 to 8 Years)</title>
          <description>Two injections of the comparator influenza vaccine were administered intramuscularly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="460"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="400"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced transiently</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>dysentery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>eye injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ovarian epithelial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthmatic crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="460"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="235" subjects_at_risk="460"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="400"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="199"/>
                <counts group_id="E5" subjects_affected="153" subjects_at_risk="402"/>
                <counts group_id="E6" subjects_affected="91" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="460"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="233"/>
                <counts group_id="E3" events="24" subjects_affected="18" subjects_at_risk="400"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E5" events="19" subjects_affected="18" subjects_at_risk="402"/>
                <counts group_id="E6" events="14" subjects_affected="12" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="51" subjects_affected="47" subjects_at_risk="460"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="233"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="400"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E5" events="28" subjects_affected="26" subjects_at_risk="402"/>
                <counts group_id="E6" events="14" subjects_affected="12" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="460"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="233"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="400"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="402"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Injection Site Haemorrhage</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="460"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="233"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="400"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E5" events="28" subjects_affected="26" subjects_at_risk="402"/>
                <counts group_id="E6" events="14" subjects_affected="13" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="460"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="233"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="400"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="199"/>
                <counts group_id="E5" events="24" subjects_affected="23" subjects_at_risk="402"/>
                <counts group_id="E6" events="18" subjects_affected="16" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="121" subjects_affected="117" subjects_at_risk="460"/>
                <counts group_id="E2" events="70" subjects_affected="70" subjects_at_risk="233"/>
                <counts group_id="E3" events="120" subjects_affected="117" subjects_at_risk="400"/>
                <counts group_id="E4" events="58" subjects_affected="58" subjects_at_risk="199"/>
                <counts group_id="E5" events="129" subjects_affected="97" subjects_at_risk="402"/>
                <counts group_id="E6" events="75" subjects_affected="59" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="460"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="233"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="400"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="199"/>
                <counts group_id="E5" events="37" subjects_affected="34" subjects_at_risk="402"/>
                <counts group_id="E6" events="24" subjects_affected="20" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="61" subjects_affected="56" subjects_at_risk="460"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="233"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="400"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="199"/>
                <counts group_id="E5" events="41" subjects_affected="37" subjects_at_risk="402"/>
                <counts group_id="E6" events="19" subjects_affected="19" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="460"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="233"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="400"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E5" events="12" subjects_affected="10" subjects_at_risk="402"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="74" subjects_affected="66" subjects_at_risk="460"/>
                <counts group_id="E2" events="39" subjects_affected="38" subjects_at_risk="233"/>
                <counts group_id="E3" events="36" subjects_affected="35" subjects_at_risk="400"/>
                <counts group_id="E4" events="26" subjects_affected="25" subjects_at_risk="199"/>
                <counts group_id="E5" events="41" subjects_affected="34" subjects_at_risk="402"/>
                <counts group_id="E6" events="19" subjects_affected="17" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="133" subjects_affected="111" subjects_at_risk="460"/>
                <counts group_id="E2" events="54" subjects_affected="45" subjects_at_risk="233"/>
                <counts group_id="E3" events="56" subjects_affected="52" subjects_at_risk="400"/>
                <counts group_id="E4" events="29" subjects_affected="23" subjects_at_risk="199"/>
                <counts group_id="E5" events="46" subjects_affected="41" subjects_at_risk="402"/>
                <counts group_id="E6" events="30" subjects_affected="26" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="460"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="233"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="400"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="402"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Novartis Vaccines and Diagnostics</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegContactVacUS.nvdit@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

